Cybin provides corporate update and highlights upcoming clinical milestones

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline. “with the prevalence and burden of mental health conditions at an all-time high, there is.
CYBN Ratings Summary
CYBN Quant Ranking